GO
Loading...

Mylan Inc

More

  • WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • Humana and Nokia are big market movers Tuesday, 8 Apr 2014 | 4:45 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Nokia Corp., up 36 cents to $7.58. China approved the sale of the communication company's mobile phone unit to Microsoft, removing one of the last major hurdles for the $7.3 billion deal.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Inc on Monday asked the U.S. Supreme Court to prevent an appeals court ruling from going into effect while the justices consider the company's appeal in a patent fight over top-selling multiple sclerosis drug Copaxone.

  • GameStop and Halozyme are big market movers Friday, 4 Apr 2014 | 4:38 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Anadarko Petroleum Corp., up $2.03 to $101.05. CarMax Inc., down $2 to $45.56.

  • *E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.

  • *E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.

  • *E* Trade and Netflix weigh on the S&P 500 and the Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Biogen Idec Inc fell 3.6 percent to $291.

  • *Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. Biogen Idec Inc fell 4.3 percent to $288.98.

  • Meda turns down approach from Mylan Friday, 4 Apr 2014 | 10:44 AM ET

    NEW YORK— Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions." Shares of Mylan Inc. rose $3.52, or 7 percent, to $53.38 in morning trading.

  • *Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. "Overall, people are taking this as a sign there isn't some sort of underlying weakness in the economy," said Kate Warne, investment strategist at Edward Jones in St. Louis.

  • *Deal could have created a $24 billion generic drugs group. STOCKHOLM, April 4- Sweden's Meda AB said on Friday it had rejected a takeover approach by U.S. generic drugmaker Mylan Inc, scuppering a potential deal to create a combined company worth around $24 billion.

  • US STOCKS-Futures rise ahead of payrolls report Friday, 4 Apr 2014 | 7:29 AM ET

    *Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. NEW YORK, April 4- U.S. stock index futures advanced modestly on Friday, putting the S&P 500 on track to hold near its record high, ahead of the monthly payrolls report.

  • *Deal could create a $23 billion drug company. STOCKHOLM, April 4- Shares in drug maker Meda AB were halted on Friday following a media report that Mylan Inc is looking to acquire its smaller Swedish rival in a move that would create a $23 billion company.

  • *Deal could create a $23 billion drug company. *Meda confirms has had initial talks with Mylan- report. STOCKHOLM, April 4- Generic drug maker Mylan Inc is looking to buy Swedish rival Meda AB in a deal that would create a $23 billion pharmaceutical company, the Financial Times reported.

  • April 3- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

Most Popular Video

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.

Thursday, 17 Apr 2014 | 11:40 AM ET

CNBC's Dominic Chu and Art Cashin, of UBS, discuss market fluctuations over the last week, as well as the credible reversal rally. He's still keeping an eye on Ukraine, and says there may be economic fallout if there are new sanctions against Russia.

Thursday, 17 Apr 2014 | 12:09 PM ET

CNBC's Scott Cohn reports Hampshire Hotel CEO Sant Singh Chatwal pleaded guilty in a campaign scheme.